InMed Pharmaceuticals Inc., announced today that it has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO") relating to the treatment of Epidermolysis Bullosa Simplex (EBS) using novel formulations of natural cannabinoid compounds developed by InMed.
Dr. Sazzad Hossain, InMed Pharmaceuticals' Chief Scientific Officer, commented, "We are excited to file our first patent covering the use of our products in a high-value orphan disease category. Based on preliminary studies, our compounds are expected to positively address the significant medical needs of EBS by promoting improvement of the key hallmarks of the disease (anti-itching, wound healing, anti-microbial, pain, anti-inflammation). We are continuing the process to build our IP within the dermatology area, adding further value to our pipeline of novel therapeutics."
A provisional patent application is a legal document that establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals that may want to file for a patent with similar claims after the filing date of our provisional application.
InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the Company.
ON BEHALF OF THE BOARD
InMed Pharmaceuticals Inc.
President and Chief Executive Officer
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
Amy Wheeler (Media)